×
About 26,705 results

ALLMedicine™ Glioblastoma Center

Research & Reviews  9,829 results

F-Box Protein 11 Suppresses Cell Proliferation and Aerobic Glycolysis in Glioblastomas ...
https://doi.org/10.1093/jnen/nlac033
Journal of Neuropathology and Experimental Neurology; Liu C, Chen X et. al.

May 19th, 2022 - Glioblastoma is a malignant CNS tumor with an extremely poor prognosis. F-box protein 11 (FBXO11) has E3 ubiquitin ligase activity and participates in the pathogenesis of multiple tumors but the role and mechanism of FBXO11 activity in glioblastom...

A Window of Opportunity to Overcome Therapeutic Failure in Neuro-Oncology.
https://doi.org/10.1200/EDBK_349175
American Society of Clinical Oncology Educational Book. A... Vogelbaum MA, Li G et. al.

May 18th, 2022 - Glioblastoma is the most common primary malignant brain neoplasm and it remains one of the most difficult-to-treat human cancers despite decades of discovery and translational and clinical research. Many advances have been made in our understandin...

PLGA-nano-encapsulated Disulfiram inhibits hypoxia-induced NFκB, cancer stem cells and ...
https://doi.org/10.1158/1535-7163.MCT-22-0066
Molecular Cancer Therapeutics; Kannappan V, Liu Y et. al.

May 18th, 2022 - Glioblastoma stem cell (GSC) is the major cause of glioblastoma multiforme (GBM) chemotherapy failure. Hypoxia is one of the determinants of GSC. NFκB plays a pivotal link between hypoxia and cancer stem cells (CSCs). Disulfiram (DS), an antialcoh...

A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with re...
https://doi.org/10.2217/cns-2022-0005
CNS Oncology; Groot J, Ott M et. al.

May 17th, 2022 - Aim: To ascertain the maximum tolerated dose (MTD)/maximum feasible dose (MFD) of WP1066 and p-STAT3 target engagement within recurrent glioblastoma (GBM) patients. Patients & methods: In a first-in-human open-label, single-center, single-arm 3 + ...

see more →

Guidelines  15 results

Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.
https://doi.org/10.1200/JCO.21.02036
Journal of Clinical Oncology : Official Journal of the Am... Mohile NA, Messersmith H et. al.

Dec 14th, 2021 - To provide guidance to clinicians regarding therapy for diffuse astrocytic and oligodendroglial tumors in adults. ASCO and the Society for Neuro-Oncology convened an Expert Panel and conducted a systematic review of the literature. Fifty-nine rand...

SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785619
Clinical & Translational Oncology : Official Publication ... Martínez-Garcia M, Álvarez-Linera J et. al.

Nov 1st, 2017 - Glioblastoma (GB) is the most common brain malignancy and accounts for over 50% of all high-grade gliomas. Radiotherapy (RT) with concomitant and adjuvant temozolomide (TMZ) chemotherapy is the current standard of care for patients with newly diag...

Radiation therapy for glioblastoma
https://www.practicalradonc.org/cms/attachment/2060190091/2062532264/mmc1.pdf?code=prro-site

Apr 17th, 2017 - The guideline addresses four areas regarding effective treatment of glioblastoma with radiation therapy. First, it provides recommendations on when radiation is indicated following biopsy or resection of glioblastoma and how it is impacted by syst...

Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Prac...
https://doi.org/10.1200/JOP.2016.018937
Journal of Oncology Practice; Sulman EP, Ismaila N et. al.

Dec 3rd, 2016 - Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline.|2016|Sulman EP,Ismaila N,Chang SM,|radiotherapy,standards,standards,

Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Prac...
https://doi.org/10.1200/JCO.2016.70.7562
Journal of Clinical Oncology : Official Journal of the Am... Sulman EP, Ismaila N et. al.

Nov 29th, 2016 - Purpose The American Society for Radiation Oncology (ASTRO) produced an evidence-based guideline on radiation therapy for glioblastoma. Because of its relevance to the ASCO membership, ASCO reviewed the guideline and applied a set of procedures an...

see more →

Drugs  29 results see all →

Clinicaltrials.gov  401 results

Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
https://clinicaltrials.gov/ct2/show/NCT02709226

May 13th, 2022 - Background Although the survival of gliomas has improved, most high grade gliomas will recur in field or adjacent to the treatment field within months to years of the original treatment. In newly diagnosed GBM, the concurrent use of radiation and ...

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
https://clinicaltrials.gov/ct2/show/NCT04817254

May 13th, 2022 - Background: Glioblastoma (GBM) represents an aggressive malignancy with limited therapeutic options. The immunosuppressive nature of GBM may be reversible with immune checkpoint inhibitor (ICI) treatment, however, initial studies have yet to demon...

Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma
https://clinicaltrials.gov/ct2/show/NCT05226494

May 13th, 2022 - Glioblastoma is a highly aggressive and fatal form of primary malignant brain tumor with limited treatment options. fb-PMT affects a large group of cancer cell signaling pathways and thus may be effective in heterogeneous, treatment-resistant tumo...

Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
https://clinicaltrials.gov/ct2/show/NCT04941274

May 13th, 2022 - Background: Kaposi Sarcoma (KS) is a multicentric angioproliferative tumor, caused by Kaposi sarcoma-associated herpesvirus, that most frequently involves the skin, but may also involve lymph nodes, lungs, bone and gastrointestinal tract. It is mo...

Restrictive Use of Dexamethasone in Glioblastoma
https://clinicaltrials.gov/ct2/show/NCT04266977

May 11th, 2022 - Background Glioblastoma (GBM) is the most common and devastating malignant brain tumor in adults. Patients with glioblastoma face a poor prognosis. Despite maximal treatment, most patients suffer tumor progression after 6-7 months and die within 1...

see more →

News  403 results

Collagen 'Tile' Delivers Postsurgical Radiation in Glioblastoma
https://www.medscape.com/viewarticle/973552

May 6th, 2022 - Following tumor removal in patients with recurrent glioblastoma, an absorbable collagen tile can deliver a controlled and therapeutic dose of radiation that targets remaining tumor cells and spares healthy tissue, new research suggests. The result...

Total Resection for Glioblastoma Predicts Longer Survival
https://www.medscape.com/viewarticle/972791

Apr 27th, 2022 - The study covered in this summary was published on researchsquare.com as a preprint and has not yet been peer reviewed. Key Takeaway Gross total resection is an independent predictor of longer survival and good postoperative functional recovery in...

Stop Calling It Cancer; AI Gets a Win in Bladder Cancer; Lack of Price Transparency
https://www.medpagetoday.com/hematologyoncology/prostatecancer/98370

Apr 22nd, 2022 - A group of prostate cancer specialists, joined by MedPage Today contributor and prostate cancer patient Howard Wolinsky, made a case to stop referring to low-grade prostate cancer (Gleason ≤6) as cancer. (Journal of Clinical Oncology) The Internat...

Long-Term Temozolomide in Patients With Glioblastoma
https://www.medscape.com/viewarticle/971991

Apr 12th, 2022 - The study covered in this summary was published on ResearchSquare.com as a preprint and has not yet been peer reviewed. Key Takeaways Patients with glioblastoma (GBM) who completed 12 cycles of temozolomide (TMZ) with Karnofsky performance status ...

Targeted Combo Notches Rare Success in Glioblastoma
https://www.onclive.com/view/targeted-combo-notches-rare-success-in-glioblastoma

Mar 30th, 2022 - For more than 20 years, investigators have tried numerous targeted therapy strategies against glioblastoma (GBM) that have fallen frustratingly short in establishing clinical benefit.1 That changed in November 2021 when an international team of in...

see more →

Patient Education  5 results see all →